Axiom Investors LLC DE Invests $8.96 Million in GeneDx Holdings Corp. $WGS

Axiom Investors LLC DE purchased a new position in GeneDx Holdings Corp. (NASDAQ:WGS) during the 4th quarter, HoldingsChannel reports. The fund purchased 68,855 shares of the company’s stock, valued at approximately $8,955,000.

Several other institutional investors have also recently made changes to their positions in WGS. Royal Bank of Canada grew its position in GeneDx by 30.2% in the first quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock worth $2,611,000 after acquiring an additional 6,840 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in GeneDx by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after acquiring an additional 453 shares in the last quarter. NewEdge Advisors LLC grew its position in GeneDx by 270,700.0% in the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock worth $240,000 after acquiring an additional 2,707 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in GeneDx by 67.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock worth $2,500,000 after acquiring an additional 11,375 shares in the last quarter. Finally, Cetera Investment Advisers purchased a new position in GeneDx in the second quarter worth $249,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Stock Up 8.7%

Shares of NASDAQ:WGS opened at $56.33 on Wednesday. The stock’s 50-day moving average price is $55.24 and its 200-day moving average price is $91.57. GeneDx Holdings Corp. has a 12-month low of $32.21 and a 12-month high of $170.87. The stock has a market capitalization of $1.67 billion, a P/E ratio of -21.02 and a beta of 1.96. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The company had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. During the same period last year, the business posted ($0.23) earnings per share. On average, equities analysts anticipate that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

GeneDx News Summary

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Director Casdin Capital, LLC bought 50,000 shares at an average price of $52.86, adding to a recent buying streak that may signal confidence from a major insider. SEC filing
• Positive Sentiment: Casdin Capital also disclosed a larger purchase of 150,000 shares at $56.44 on June 4, reinforcing the impression of insider accumulation after the stock’s recent weakness. SEC filing
• Neutral Sentiment: GeneDx also presented at Goldman Sachs’ Global Healthcare Conference, which may have helped keep the stock in focus, but no major new operating update was highlighted in the transcript. Conference transcript
• Neutral Sentiment: Analyst sentiment remains mixed-to-positive overall, with the stock carrying an average “Moderate Buy” rating, though that view has not changed the near-term legal headline risk. Analyst rating update
• Negative Sentiment: Several law firms issued fresh class-action notices and lead-plaintiff reminders tied to GeneDx’s stock drop after its Q1 results, keeping investor attention on potential securities-fraud claims and litigation uncertainty. Class action alert
• Negative Sentiment: The lawsuits center on alleged misleading disclosures and a steep post-earnings selloff, which may continue to weigh on sentiment despite insider buying. Litigation report

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Jefferies Financial Group set a $150.00 target price on shares of GeneDx in a research report on Monday, February 23rd. Zacks Research lowered shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 24th. Wall Street Zen lowered shares of GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Wells Fargo & Company reiterated an “overweight” rating and issued a $75.00 target price (down from $155.00) on shares of GeneDx in a research report on Tuesday, May 5th. Finally, Piper Sandler restated an “overweight” rating and set a $130.00 price target (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $96.43.

Insider Transactions at GeneDx

In other news, Director Casdin Capital, Llc bought 185,000 shares of the company’s stock in a transaction dated Tuesday, May 19th. The stock was bought at an average cost of $42.60 per share, for a total transaction of $7,881,000.00. Following the completion of the acquisition, the director owned 3,367,164 shares in the company, valued at approximately $143,441,186.40. This trade represents a 5.81% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Keith A. Meister bought 533,758 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were purchased at an average price of $37.86 per share, with a total value of $20,208,077.88. Following the completion of the acquisition, the director owned 3,761,908 shares of the company’s stock, valued at $142,425,836.88. This trade represents a 16.53% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have bought 2,256,420 shares of company stock worth $93,144,340 and have sold 72,382 shares worth $4,889,473. 29.60% of the stock is currently owned by company insiders.

GeneDx Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.